Drugs / FOSFOCREATINE

Trials 3 · a red edge is where a trial was stopped

2017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT03138681 May 2017 → Apr 2019 major depressive disorder Zhujiang Hospital Unknown No outcome recorded
Phase 32 trials
Phase 3 NCT06503016 Oct 2024 → Apr 2026 overdue bronchial disorder, cardiac arrest, heart failure, hypotensive disorder +1 Vita-Salute San Raffaele University Recruiting No outcome recorded
Phase 3 NCT02757443 Jun 2016 → Apr 2021 cardiac valvular defect Meshalkin Research Institute of Pathology of Circulation Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT05431413 Comparator Jan 2020 → Dec 2025 depressive disorder Nanfang Hospital, Southern Medical University Unknown No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as FOSFOCREATINE ChEMBL registry synonym — accepted as the source's own label CHEMBL1204644
Known as Creatine phosphate ChEMBL registry synonym — accepted as the source's own label CHEMBL1204644
Known as Creatine-p ChEMBL registry synonym — accepted as the source's own label CHEMBL1204644
Known as PCr “Previous studies have revealed that the decrease of bio-energetic metabolism may contribute to the occurrence of depression, while our team has found adenosine triphosphate...” PMID 30626424 Jan 2019
1

“2 g of Phosphocreatine (PCr) prepared in 50 mL of glucose 5% during 30 min intravenous (IV)” NCT02757443

Known as Phosphagen ChEMBL registry synonym — accepted as the source's own label CHEMBL1204644
Known as Phosphocreatine ClinicalTrials.gov intervention name — accepted as the source's own label NCT06503016
3

NCT03138681

NCT02757443

NCT05431413

Modality Small molecule CHEMBL1204644
Route Intravenous “during 30 min intravenous (IV)” NCT02757443